Document:

Exhibit
4.3

 

Execution Version

 

 

 

bioAffinity
Technologies, Inc.

 

and

 

VStock
Transfer, LLC, as Warrant Agent

 

 

 

Warrant
Agent Agreement

 

    	 

     

    

 

WARRANT
AGENT AGREEMENT

 

This
WARRANT AGENT AGREEMENT (this “Warrant Agreement”), dated as of September 6, 2022 (the “Initial Exercise
Date”) is between bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), and VStock Transfer,
LLC, a California limited liability company (the “Warrant Agent”).

 

W
I T N E S E T H

 

WHEREAS,
pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated August 31, 2022, by
and among the Company and WallachBeth Capital, LLC, as representative of the underwriters set forth therein (the “Representative”),
the Company is engaged in a public offering (the “Offering”) of up to 1,282,600 units (each, a “Unit,”
collectively, the “Units”) at an initial public offering price of $6.125 per Unit, each Unit consisting of (i) one
share (collectively, the “Shares”) of common stock, par value $0.007 per share (the “Common Stock”)
of the Company, (ii) one five-year tradeable warrant (each, a “Tradeable Warrant”) to purchase one share of Common
Stock (“Tradeable Warrant Shares”) at an exercise price of $7.35 per share, and (iii) one five-year non-tradeable
warrant (a “Non-tradeable Warrant”; together with each Tradeable Warrant, the “Warrants”) to purchase
one share of Common Stock (“Non-tradeable Warrant Shares; together with the Tradeable Warrant Shares, the “Warrant
Shares”) at an exercise price of $7.656 per share, which includes the Shares, Warrants, and Warrant Shares issuable pursuant
to the over-allotment option granted to the underwriters (the “Over-Allotment Option”), and the warrant and 25,652
Warrant Shares underlying the warrant issued to the Representative (the “Representative’s Warrant”);

 

WHEREAS,
the Company has filed with the Securities and Exchange Commission (the “Commission”) a Registration Statement, File
No. 333-264463, on Form S-1 (as the same may be amended from time to time, the “Registration Statement”), for the
registration under the Securities Act of 1933, as amended (the “Securities Act”), of the Units, the Shares, the Warrants,
the Warrant Shares, the Representative’s Warrant, and the Over-Allotment Option, and such Registration Statement was declared effective
on August 29, 2022;

 

WHEREAS,
pursuant to the Registration Statement and the registered offering made thereby, the Company wishes to issue Warrants in book-entry form
entitling the respective holders of the Warrants (the “Holders,” which term shall include a Holder’s transferees,
successors, and assigns; and each, a “Holder,” which term shall include, if the Warrants are held in “street
name,” a Participant (as defined below) or a designee appointed by such Participant) to purchase an aggregate of up to 2,565,200
Shares of Common Stock issuable upon exercise of the Warrants underlying the Units sold in the offering upon the terms and subject to
the conditions hereinafter set forth (the “Offering”);

 

WHEREAS,
the Shares, the Tradeable Warrants, and the Non-tradeable Warrants to be issued in connection with the Offering shall be immediately
separable and will be issued separately but will be purchased together, as Units, in the Offering;

 

    	 

     

    

 

WHEREAS
the Company wishes the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in accordance with
the terms set forth in this Warrant Agreement in connection with the issuance, registration, transfer, exchange, exercise, and replacement
of the Warrants and to advise and direct the Company on the delivery of the Warrant Shares;

 

WHEREAS,
the Company desires to provide for the provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective
rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants; and

 

WHEREAS,
all acts and things have been done and performed which are necessary to make the Warrants the valid, binding and legal obligations of
the Company, and to authorize the execution and delivery of this Warrant Agreement.

 

NOW,
THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

Section
1. Certain Definitions. For purposes of this Warrant Agreement, the following terms have the meanings indicated:

 

(a) “Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

(b) “Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (i) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30:01
a.m. (New York City time) to 4:00:00 p.m. (New York City time)), (ii) if the Common Stock is not listed or quoted on a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(iii) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported
on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (iv) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

(c) Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States, or any day
on which commercial banks in The City of New York are authorized or required by law to remain closed; provided, however,
for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to “stay at home”,
“shelter-in-place”, “non-essential employee” or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including
for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.

 

    	2

    	 

    

 

(d) “Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock

 

(e) “Non-tradeable
Warrant Certificate” means a certificate in substantially the form attached as Exhibit 2 hereto, representing such number
of Non-tradeable Warrant Shares as is indicated therein, provided that any reference to the delivery of a Non-tradeable Warrant Certificate
in this Warrant Agreement shall include delivery of a Definitive Certificate or a Non-tradeable Global Warrant (each as defined below).

 

(f) “Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

(g) “Tradeable
Warrant Certificate” means a certificate in substantially the form attached as Exhibit 1 hereto, representing such number
of Tradeable Warrant Shares as is indicated therein, provided that any reference to the delivery of a Tradeable Warrant Certificate in
this Warrant Agreement shall include delivery of a Definitive Certificate or a Tradeable Global Warrant (each as defined below).

 

(h) “Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

 

(i) “Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange
(or any successors to any of the foregoing).

 

(j) VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (i) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30:01
a.m. (New York City time) to 4:00:00 p.m. (New York City time)); (ii) if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, ; (iii) if the Common
Stock are not then listed or quoted for trading on the OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent Bid Price per share
of the Common Stock so reported; or (iv) in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable
to Company, the fees and expenses of which shall be paid by the Company.

 

(k) “Warrant
Certificates” means the Tradeable Warrant Certificates and the Non-tradeable Warrant Certificates.

 

    	3

    	 

    

 

(l) “Warrant
Shares” means shares of Common Stock underlying the Warrants and issuable upon exercise of the Warrants.

 

All
other capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Warrant Certificates.

 

Section
2. Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company in accordance
with the terms and conditions hereof, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance
with the express terms and conditions set forth in this Warrant Agreement (and no implied terms or conditions).

 

Section
3. Global Warrants.

 

(a) The
Tradeable Warrants shall be registered securities and shall be evidenced by a global warrant (a “Tradeable Global Warrant”),
in the form of the Tradeable Warrant Certificate, which shall be deposited with the Warrant Agent and registered in the name of Cede
& Co., a nominee of The Depository Trust Company (the “Depositary”), or as otherwise directed by the Depositary.
The Non-tradeable Warrants will be unregistered securities and will be evidenced by a global warrant (a “Non-tradeable Global
Warrant”; together with each Tradeable Global Warrant, the “Global Warrants”), in the form of the Non-tradeable
Warrant Certificate, which shall be deposited on behalf of the Company with the Warrant Agent. Ownership of security entitlements in
the Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained (i) in the case of Tradeable
Warrants, by (A) the Depositary or its nominee for each Tradeable Global Warrant, or (B) institutions that have accounts with the Depositary
(such institution, with respect to a Warrant in its account, a “Participant”), and (ii) in the case of Non-tradeable
Warrants, by the Warrant Agent.

 

(b) If
the Depositary subsequently ceases to make its book-entry settlement system available for the Tradeable Warrants, the Company may instruct
the Warrant Agent regarding other arrangements for book-entry settlement. In the event that the Tradeable Warrants are not eligible for,
or it is no longer necessary to have the Tradeable Warrants available in, book-entry form, the Warrant Agent shall provide written instructions
to the Depositary to deliver to the Warrant Agent for cancellation each Tradeable Global Warrant, and the Company shall deliver, or shall
instruct the Warrant Agent to deliver, to each Holder a Tradeable Warrant Certificate.

 

    	4

    	 

    

 

(c) A
Holder has the right to elect at any time or from time to time a Warrant Exchange (as defined below) pursuant to a Warrant Certificate
Request Notice (as defined below). Upon written notice by a Holder to the Warrant Agent for the exchange of some or all of such Holder’s
Global Warrants for a separate certificate (a “Definitive Certificate”), in the form attached hereto as Exhibit
1 with respect to a Holder of Tradeable Global Warrants or Exhibit 2 with respect to a Holder of Non-tradeable Global Warrants,
evidencing the same number of Warrants, which request shall be in the form attached hereto as Annex A (a “Warrant Certificate
Request Notice” and the date of delivery of such Warrant Certificate Request Notice by the Holder, the “Warrant Certificate
Request Notice Date” and the deemed surrender upon delivery by the Holder of a number of Global Warrants for the same number
of Warrants evidenced by a Warrant Certificate, a “Warrant Exchange”), the Warrant Agent shall promptly effect the
Warrant Exchange and shall promptly issue and deliver to the Holder a Definitive Certificate for such number of Warrants in the name
set forth in the Warrant Certificate Request Notice. Such Definitive Certificate shall be dated the original issue date of the Warrants,
shall be executed on behalf of the Company by its Chief Executive Officer or Chief Financial Officer by facsimile signature and by an
authorized signatory of the Warrant Agent, shall be in the form attached hereto as Exhibit 1 with respect to Tradeable Global
Warrants or Exhibit 2 with respect to Non-tradeable Global Warrants, and shall be reasonably acceptable in all respects to such
Holder. In connection with a Warrant Exchange, the Company agrees to deliver, or to direct the Warrant Agent to deliver, the Definitive
Certificate to the Holder within three (3) Business Days of the Warrant Certificate Request Notice pursuant to the delivery instructions
in the Warrant Certificate Request Notice (“Warrant Certificate Delivery Date”). If the Company fails for any reason
to deliver to the Holder the Definitive Certificate subject to the Warrant Certificate Request Notice by the Warrant Certificate Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares evidenced
by such Definitive Certificate (based on the VWAP (as defined in the Warrants) of the Common Stock on the Warrant Certificate Request
Notice Date), $10 per Business Day (increasing to $20 per Business Day on the fifth Business Day after such liquidated damages begin
to accrue) for each Business Day after such Warrant Certificate Delivery Date until such Definitive Certificate is delivered or, prior
to delivery of such Warrant Certificate, the Holder rescinds such Warrant Exchange. The Company covenants and agrees that, upon the date
of delivery of the Warrant Certificate Request Notice, the Holder shall be deemed to be the holder of the Definitive Certificate and,
notwithstanding anything to the contrary set forth herein, the Definitive Certificate shall be deemed for all purposes to contain all
of the terms and conditions of the Warrants evidenced by such Warrant Certificate and the terms of this Warrant Agreement, other than
Section 3(c) and Section 10 herein, which shall not apply to the Warrants evidenced by the Definitive Certificate. For purposes of clarity,
the Warrant Agent may act as warrant agent on behalf of the Company with respect to any Definitive Certificate requested and issued pursuant
to this section, provided that the terms of this Warrant Agreement shall not apply to the Definitive Certificate and the terms of the
Definitive Certificate shall exclusively govern. Notwithstanding anything to the contrary contained in this Warrant Agreement, in the
event of inconsistency between any provision in this Warrant Agreement and any provision in a Definitive Certificate, as it may from
time to time be amended, the terms of such Definitive Certificate shall control.

 

Section
4. Form of Warrants. The Tradeable Warrant Certificate, together with the form of election to purchase Common Stock (the “Notice
of Exercise”) provided in Exhibit 3 hereto and the form of assignment provided in Exhibit 4 hereto to be printed
on the reverse thereof, shall be in the form of Exhibit 1 hereto. The Non-tradeable Warrant Certificate, together with the form
of Notice of Exercise and the form of assignment to be printed on the reverse thereof, shall be in the form of Exhibit 2 hereto.

 

    	5

    	 

    

 

Section
5. Countersignature and Registration.

 

(a) The
Warrant Certificates shall be executed on behalf of the Company by its Chief Executive Officer or Chief Financial Officer by facsimile
signature and by an authorized signatory of the Warrant Agent, which need not be the same signatory for all of the Warrant Certificates.
No Warrant Certificate shall be valid for any purpose unless so countersigned. In case any officer of the Company who shall have signed
any of the Warrant Certificates shall cease to be such officer of the Company before countersignature by the Warrant Agent and issuance
and delivery by the Company, such Warrant Certificates, nevertheless, may be countersigned by the Warrant Agent, issued and delivered
with the same force and effect as though the person who signed such Warrant Certificate had not ceased to be such officer of the Company;
and any Warrant Certificate may be signed on behalf of the Company by any person who, at the actual date of the execution of such Warrant
Certificate, shall be a proper officer of the Company to sign such Warrant Certificate, although at the date of the execution of this
Warrant Agreement any such person was not such an officer.

 

(b) The
Warrant Agent will keep or cause to be kept, at one of its offices, or at the office of one of its agents, books for registration and
transfer of the Warrant Certificates issued hereunder. Such books shall show the names and addresses of the respective Holders of the
Warrant Certificates, the number of warrants evidenced on the face of each of such Warrant Certificate and the date of each of such Warrant
Certificate.

 

Section
6. Transfer, Split Up, Combination and Exchange of Warrant Certificates; Mutilated, Destroyed, Lost or Stolen Warrant Certificates.

 

(a) With
respect to each Global Warrant, subject to the provisions of the applicable Warrant Certificate and the last sentence of this Section
6(a) and subject to applicable law, rules or regulations, or any “stop transfer” instructions the Company may give to the
Warrant Agent, at any time after the closing date of the Offering, and at or prior to the Close of Business on the Termination Date (as
defined below), any Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants may be transferred, split up, combined
or exchanged for another Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants, entitling the Holder to purchase
a like number of shares of Common Stock as the Warrant Certificate or Warrant Certificates or Global Warrant or Global Warrants surrendered
then entitled such Holder to purchase. Any Holder desiring to transfer, split up, combine or exchange any Warrant Certificate or Global
Warrant shall make such request in writing delivered to the Warrant Agent, and shall surrender the Warrant Certificate or Warrant Certificates
to be transferred, split up, combined or exchanged at the principal office of the Warrant Agent, provided that no such surrender is applicable
to the Holder of a Global Warrant. Any requested transfer of Warrants, whether in book-entry form or certificate form, shall be accompanied
by reasonable evidence of authority of the party making such request that may be required by the Warrant Agent. Thereupon the Warrant
Agent shall, subject to the last sentence of this Section 6(a), countersign and deliver to the Person entitled thereto a Warrant Certificate
or Warrant Certificates, as the case may be, as so requested. The Company may require payment from the Holder of a sum sufficient to
cover any tax or governmental charge that may be imposed in connection with any transfer, split-up, combination or exchange of Warrant
Certificates, together with reimbursement to the Company and the Warrant Agent of all reasonable expenses incidental thereto.

 

    	6

    	 

    

 

(b) Upon
receipt by the Warrant Agent of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of a Warrant Certificate,
which evidence shall include an affidavit of loss, or in the case of mutilated certificates, the certificate or portion thereof remaining,
and, in case of loss, theft or destruction, of indemnity or security in customary form and amount (but shall not include the posting
of any bond by the Holder), and satisfaction of any other reasonable requirements established by Section 8-405 of the Uniform Commercial
Code as in effect in the State of Delaware, and reimbursement to the Company and the Warrant Agent of all reasonable expenses incidental
thereto, and upon surrender to the Warrant Agent and cancellation of the Warrant Certificate if mutilated, the Company will make and
deliver a new Warrant Certificate of like tenor to the Warrant Agent for delivery to the Holder in lieu of the Warrant Certificate so
lost, stolen, destroyed or mutilated. The Warrant Agent may charge the Holder an administrative fee for processing the replacement of
lost Warrant Certificates, which shall be charged only once in instances where a single surety bond obtained covers multiple certificates.
The Warrant Agent may receive compensation from the surety companies or surety agents for administrative services provided to them

 

Section
7. Issuance of Warrants. Upon the initial issuance of the Tradeable Warrants, the Warrant Agent shall issue the Tradeable Warrant
Certificate and deliver the Tradeable Warrants in the Depositary book-entry settlement system in accordance with written instructions
delivered to the Warrant Agent by the Company. Upon the initial issuance of the Non-tradeable Warrants, the Warrant Agent shall issue
the Non-tradeable Warrants in the Warrant Agent’s book-entry system in accordance with the Company’s written instructions
delivered to the Warrant Agent and provide to the Company an account statement reflecting the issuance of the Non-tradable Warrants.

 

(a) Beneficial
Owner; Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and
treat the Person in whose name that Warrant shall be registered on the Warrant Register as the absolute owner of such Warrant for purposes
of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to
the contrary. Notwithstanding the foregoing, nothing herein shall prevent the Company, the Warrant Agent or any agent of the Company
or the Warrant Agent from giving effect to any written certification, proxy or other authorization furnished by the Depositary governing
the exercise of the rights of a Holder of a beneficial interest in any Tradeable Warrant. The rights of beneficial owners in a Warrant
evidenced by the Warrant Certificates shall be exercised by the Holder or a Participant through (i) in the case of a Tradeable Warrant,
the Depositary system, or (ii) in the case of a Non-tradeable Warrant, the Warrant Agent’s system, except to the extent set forth
herein or in the Warrant Certificates.

 

(b) Proxies.
The Holder of a Warrant may grant proxies or otherwise authorize any Person, including the Participants and beneficial holders that may
own interests through the Participants in the case of Tradeable Warrants, to take any action that a Holder is entitled to take under
this Warrant Agreement or the Warrants; provided, however, that at all times that Tradeable Warrants are evidenced by a
Tradeable Warrant Certificate, exercise of those Tradeable Warrants shall be effected on their behalf by Participants through the Depositary
in accordance the procedures administered by the Depositary.

 

Section
8. Exercise of Warrants; Exercise Price; Termination Date.

 

(a) Exercise
Price. Each Warrant shall entitle the Holder, subject to the provisions of the applicable Warrant Certificate and of this Warrant
Agreement, to purchase from the Company the number of Shares of Common Stock stated therein, at the price of (i) $7.35 per whole Share
(120% of the $6.125 per-Unit public offering price) upon exercise of a Tradeable Warrant, and (ii) $7.656 per whole Share (125% of the
$6.125 per-Unit public offering price) upon exercise of a Non-tradeable Warrant, subject in both cases to the subsequent adjustments
provided in Sections 12 and 13 hereof. The term “Exercise Price” as used in this Warrant Agreement refers to the price
per Share at which Shares of Common Stock may be purchased at the time a Warrant is exercised.

 

    	7

    	 

    

 

(b) Exercise
of Warrants. The Warrants shall be exercisable commencing on the Initial Exercise Date. The Warrants shall cease to be exercisable
and shall terminate and become void at 11:59 P.M., New York City time (the “Termination Time”) on September 1, 2027
(the “Termination Date”). Each Warrant not exercised on or before the Termination Date shall become void, and all
rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the Termination Time on the Termination
Date. Subject to the foregoing and to Section 8(e)(ii) below, the Holder of a Warrant may exercise the Warrant in whole or in part upon
surrender of the Warrant Certificate, if required, with the executed Notice of Exercise and payment of the Exercise Price, which may
be made, at the option of the Holder, by wire transfer or by certified or official bank check in United States dollars, to the Company
in the account of the Company maintained with the Warrant Agent for such purpose as set forth in Section 8(h) below (or to such other
account as directed by the Company in writing) not later than 5:00 P.M., New York City time on any Business Day during the Exercise Period.
In the case of the Holder of a Global Warrant, the Holder shall deliver the executed Notice of Exercise and the payment of the Exercise
Price pursuant to Section 8(a). Notwithstanding any other provision in this Warrant Agreement, a holder whose interest in a Global Warrant
is a beneficial interest in a Global Warrant held in book-entry form through the Depositary (or another established clearing corporation
performing similar functions), shall effect exercises by delivering to the Depositary (or such other clearing corporation, as applicable)
the appropriate instruction form for exercise, complying with the procedures to effect exercise that are required by the Depositary (or
such other clearing corporation, as applicable). No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise be required. The Company hereby acknowledges and agrees that,
with respect to a Holder whose interest in a Global Warrant is a beneficial interest in a Global Warrant held in book-entry form through
the Depositary (or another established clearing corporation performing similar functions), upon delivery of irrevocable instructions
to such Holder’s Participant to exercise such Warrants, that solely for purposes of Regulation SHO that such Holder shall be deemed
to have exercised such Warrants.

 

(c) Issuance
of Warrant Shares.

 

(i) Upon
the exercise of the Warrant Certificate pursuant to the terms of Section 2 of the Warrant Certificate, the Warrant Agent shall cause,
or shall provide notice to the Company in order that the Company shall cause, the Warrant Shares underlying such Warrant Certificate
or Global Warrant to be delivered to or upon the order of the Holder of such Warrant Certificate or Global Warrant, registered in such
name or names as may be designated by such Holder, by the earliest of (1) two Trading Days after the delivery to the Company of the Notice
of Exercise, (2) one Trading Day after delivery of the aggregate Exercise Price to the Company, and (3) the number of Trading Days comprising
the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to
the Common Stock as in effect on the date of the delivery to the Company of the Notice of Exercise (such date, the “Warrant
Share Delivery Date”). If the Company is then a participant in the Deposit Withdrawal Agent Commission (“DWAC”)
system of the Depositary and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to
or resale of the Warrant Shares by Holder or (B) the Warrant is being exercised via cashless exercise pursuant to Section 2(c) of the
Warrant (a “Cashless Exercise”), then the certificates for Warrant Shares shall be transmitted by the Warrant Agent,
or, at the direction of the Company, by the Company’s transfer agent, to the Holder by crediting the account of the Holder’s
broker with the Depositary through its DWAC system. For the avoidance of doubt, if the Company becomes obligated to pay any amounts to
any Holders pursuant to Section 2(d)(i) or 2(d)(iv) of the Warrant Certificate, such obligation shall be solely that of the Company and
not that of the Warrant Agent. Notwithstanding anything else to the contrary in this Warrant Agreement, except in the case of a Cashless
Exercise, if any Holder fails to duly deliver payment to the Warrant Agent of an amount equal to the aggregate Exercise Price of the
Warrant Shares to be purchased upon exercise of such Holder’s Warrant by the Warrant Share Delivery Date, the Warrant Agent, or,
at the direction of the Company, by the Company’s transfer agent, will not obligated to deliver such Warrant Shares (via DWAC or
otherwise) until following receipt of such payment, and the applicable Warrant Share Delivery Date shall be deemed extended by one day
for each day (or part thereof) until such payment is delivered to the Warrant Agent.

 

    	8

    	 

    

 

(ii) Valid
Issuance. All Warrant Shares issued by the Company upon the proper exercise of a Warrant in conformity with this Warrant Agreement
shall be duly authorized, validly issued, fully paid and non-assessable.

 

(iii) No
Transfer Taxes. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, the Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached to the Warrant duly executed by the Holder and the Company may require,
as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay
all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depositary (or another established
clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

(iv) Date
of Issuance. The Company will treat an exercising Holder as a beneficial owner of the Warrant Shares as of the Exercise Date, except
that, if the Exercise Date is a date when the stock transfer books of the Company are closed, such Person shall be deemed to have become
the holder of such shares at the open of business on the next succeeding date on which the stock transfer books are open.

 

(d) Any
Person so designated by the Holder (or a Participant or designee of a Participant on behalf of a Holder) to receive Warrant Shares shall
be deemed to have become holder of record of such Warrant Shares as of the time that an appropriately completed and duly signed Notice
of Exercise has been delivered to the Warrant Agent, provided that the Holder (or Participant on behalf of the Holder) makes delivery
of the deliverables referenced in Section 8(b). If the Holder (or Participant on behalf of the Holder) fails to make delivery of such
deliverables on or prior to the Trading Day following delivery of the Notice of Exercise, such Notice of Exercise shall be void ab
initio.

 

    	9

    	 

    

 

(e) Restrictive
Legend Events; Cashless Exercise Under Certain Circumstances.

 

(i) Restrictive
Legend of Tradeable Warrants. The Company shall use it reasonable best efforts to maintain the effectiveness of the Registration
Statement and the current status of the prospectus included therein or to file and maintain the effectiveness of another registration
statement and another current prospectus covering the Tradeable Warrants and the Tradeable Warrant Shares at any time that the Tradeable
Warrants are exercisable. The Company shall provide to the Warrant Agent and each Holder prompt written notice of any time that the Company
is unable to deliver the Tradeable Warrant Shares via the Depositary transfer or otherwise without restrictive legend because: (i) the
Commission has issued a stop order with respect to the Registration Statement, (ii) the Commission otherwise has suspended or withdrawn
the effectiveness of the Registration Statement, either temporarily or permanently, (iii) the Company has suspended or withdrawn the
effectiveness of the Registration Statement, either temporarily or permanently, (iv) in the case of a Tradeable Warrant, the prospectus
contained in the Registration Statement is not available for the issuance of the Tradeable Warrant Shares to the Holder, or (v) otherwise
(each a “Restrictive Legend Event”). To the extent that the Tradeable Warrants cannot be exercised as a result of
a Restrictive Legend Event or a Restrictive Legend Event occurs after a Holder has exercised Tradeable Warrants in accordance with the
terms of the Tradeable Warrants but prior to the delivery of the Tradeable Warrant Shares, the Company shall, at the election of the
Holder, which shall be given within five (5) days of receipt of such notice of the Restrictive Legend Event, either (i) rescind the previously
submitted Notice of Exercise and return all consideration paid by such registered Holder for such shares upon such rescission, or (ii)
treat the attempted exercise as a Cashless Exercise as described in Section 8(e)(i)(ii) below and refund the cash portion of the exercise
price to the Holder.

 

(ii) Cashless
Exercise. (1) If a Restrictive Legend Event has occurred, then the Holder may, in its sole discretion, exercise the Warrant in
whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment
of the aggregate exercise price, elect instead to receive upon such exercise the “Net Number” of Warrant Shares determined
according to the Cashless Exercise formula below. Notwithstanding anything herein to the contrary, the Company shall not be required
to make any cash payments or net cash settlement to the Holder in lieu of delivery of the Tradeable Warrant Shares. Upon a Cashless Exercise,
the Holder shall be entitled to receive the number of Tradeable Warrant Shares equal to the quotient obtained by dividing (A-B) (X) by
(A), where:

 

	 	(A)
     = 	as
    applicable: (i) the VWAP on the Trading Day immediately preceding the Exercise Date if the Holder’s Notice of Exercise is (1)
    both executed and delivered pursuant to Section 8(e)(i)(1) hereof on a day that is not a Trading Day, or (2) both executed and delivered
    pursuant to Section 8(e)(i)(1) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in
    Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder,
    either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise, or (z) the Bid Price
    of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution
    of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading
    Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours”
    on a Trading Day) pursuant to Section 8(e)(i)(1) hereof, or (iii) the VWAP on the date of the applicable Notice of Exercise if the
    date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 8(e)(i)(1)
    hereof after the close of “regular trading hours” on such Trading Day;

 

    	10

    	 

    

 

	 	(B)
     = 	the
    Exercise Price then in effect for the applicable Warrant Shares at the time of the exercise of the Tradeable Warrant, as adjusted
    as set forth herein; and
	 	 	 
	 	(X)
     = 	the
    number of Tradeable Warrant Shares that would be issuable upon exercise of the Tradeable Warrant in accordance with the terms of
    the Tradeable Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

 

(2) If
the Tradeable Warrant Shares are issued in such a Cashless Exercise, the Company acknowledges and agrees that, in accordance with Section
3(a)(9) of the Securities Act, the Tradeable Warrant Shares shall take on the registered characteristics of the Tradeable Warrants being
exercised and the Company agrees not to take any position contrary thereto.

 

(3) Upon
receipt of a Notice of Exercise for a Cashless Exercise pursuant to Section 2(c) of the Warrant, the Company will promptly calculate
and transmit to the Warrant Agent the number of Warrant Shares issuable in connection with such Cashless Exercise and deliver a copy
of the Notice of Exercise to the Warrant Agent, which shall issue such number of Warrant Shares in connection with such Cashless Exercise.
The Warrant Agent shall have no duty, responsibility or obligation under this section to calculate the number of Tradeable Warrant Shares
issuable in connection with any Cashless Exercise. The Warrant Agent shall be entitled to rely conclusively on any such written notice
provided by the Company, and the Warrant Agent shall not be liable for any action taken, suffered or omitted to be taken by it in accordance
with such written instructions or pursuant to this Warrant Agreement.

 

(iii) Restrictive
Legend of Non-tradeable Warrants. No registration is required for the offer and sale of the Non-tradeable Warrants by the Company
to the Holders. The Non-tradeable Warrants may only be disposed of in compliance with state and federal securities laws. In connection
with any transfer of Non-tradeable Warrants other than pursuant to an effective registration statement or Rule 144 promulgated under
the Securities Act, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor
and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to
the effect that such transfer does not require registration of such transferred Non-tradeable Warrant under the Securities Act. Certificates
evidencing the Non-tradeable Warrants shall not contain any legend: (i) while a registration statement covering the resale of such security
is effective under the Securities Act; (ii) following any sale of such Non-tradeable Warrants pursuant to Rule 144 (assuming cashless
exercise of the Non-tradeable Warrants); (iii) if such Non-tradeable Warrants are eligible for sale under Rule 144 (assuming cashless
exercise of the Non-tradeable Warrants); or (iv) if such legend is not required under applicable requirements of the Securities Act (including
judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal
opinion to the Warrant Agent or the Holder promptly if required by the Warrant Agent to effect the removal of the legend hereunder, or
if requested by a Holder, respectively. If all or any portion of a Non-tradeable Warrant is exercised at a time when a legend is not
required pursuant to clauses (i)-(iv) above, then such Non-tradeable Warrants shall be issued free of all legends.

 

    	11

    	 

    

 

(f) Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the number of Warrant Shares
issuable in connection with any exercise, the Company shall promptly deliver to the Holder the number of Warrant Shares that are not
disputed.

 

(g) Beneficial
Ownership Limitation. A Holder shall not have the right to exercise any Warrants to the extent that after giving effect to the issuance
of Warrant Shares after exercise as set forth on the applicable Notice of Exercise, such Holder or a Person holding through such Holder
(together with such Holder’s or Person’s Affiliates (as defined in Rule 405 under the Securities Act), and any other Persons
acting as a group together with that Holder or person or any of that Holder’s or person’s Affiliates (such Persons, “Attribution
Parties”)), would beneficially own in excess of 4.99% (“Beneficial Ownership Limitation”) of the Company’s
Common Stock. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
and Attribution Parties shall include the number of shares of Common Stock held by the Holder and its Affiliates and Attribution Parties
plus the number of Warrant Shares that would be owned by that Person issuable upon exercise of the Warrants with respect to which such
determination is being made, but shall exclude the number of shares of Common Stock (i) which would be issuable upon exercise of the
remaining, non-exercised Warrants beneficially owned by that Holder or any of its Affiliates or Attribution Parties and (ii) which would
be issuable upon exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including,
without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.. Except as set forth in the preceding
sentence, for purposes of this Section 8(g), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities
Exchange Act of 1934, as amended, and the rule and regulations promulgated thereunder (the “Exchange Act”), it being
acknowledged by the Holder that neither the Warrant Agent nor the Company is representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder or beneficial owner is solely responsible for any schedules required to be filed
in accordance therewith. To the extent that the limitation contained in this Section 8(g) applies, the determination of whether a Warrant
is exercisable and of which portion of the Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of
a Notice of Exercise shall be deemed to be the Holder’s determination of whether such Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and which portion of the Warrant is exercisable,
and neither the Warrant Agent nor the Company shall have any obligation to verify or confirm the accuracy of such determination and neither
of them shall have any liability for any error made by the Holder or any other Person. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 8(g), in determining the number of outstanding shares of Common Stock, a Holder or other Person
may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company’s most recent periodic or annual report
filed with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) a
more recent written notice by the Company or the Company’s transfer agent setting forth the number of shares of Common Stock outstanding
(the “Reported Outstanding Share Number”). If the Company receives a Notice of Exercise from a Holder at a time when
the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) notify
the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Notice of Exercise would
otherwise cause the Holder’s beneficial ownership to exceed the Beneficial Ownership Limitation, the Holder must notify the Company
of a reduced number of Warrant Shares to be acquired pursuant to such Notice of Exercise (the number of shares by which such purchase
is reduced, the “Reduction Shares”) and (ii) as soon as reasonably practicable, the Company shall return to the Holder
any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of a Person
that represents that it is or is acting on behalf of a Holder, the Company shall, within one (1) Trading Day, confirm orally or in writing
or by e-mail to that Person the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants,
9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. Upon delivery of a written notice to the Company, the Holder may from time to time increase or
decrease the Beneficial Ownership Limitation to any other percentage not in excess of 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
and the provisions of this Section 8(g) shall continue to apply. as specified in such notice, provided that any increase in the Beneficial
Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Company
and any such increase or decrease will apply only to the Holder and its Affiliates and Attribution Parties and not to any other holder
of Warrants. The provisions of this Section 8(g) shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 8(g) to correct this subsection (or any portion hereof) which may be defective or inconsistent with the intended
beneficial ownership limitation herein contained. The limitations contained in this Section 8(g) shall apply to a successor holder of
the Warrant.

 

    	12

    	 

    

 

(h) Deposit
of Funds. The Warrant Agent shall deposit all funds received by it in payment of the Exercise Price for all Warrants in the account
of the Company maintained with the Warrant Agent for such purpose as set forth below (or to such other account as directed by the Company
in writing) and shall advise the Company via email at the end of each day on which notices of exercise are received or funds for the
exercise of any Warrant are received of the amount so deposited to its account.

 

	 	Receiving
Bank:		Texas
                                            Partners Bank
	 	 		1900
NW Loop 410
	 	 		San
Antonio, Texas 78213
	 	 		 
	 	ABA Routing Number:	 	114025641

 

Account
Number: Money Market – 3000019111

 

Account
Name: bioAffinity Technologies, Inc.

 

Address:
22211 W I-10, Suite 1206, San Antonio, Texas 78257

 

(i) Partial
Exercise. In case the Holder of any Warrant Certificate exercises fewer than all Warrants evidenced thereby and surrenders such Warrant
Certificate in connection with such partial exercise, a new Warrant Certificate evidencing the number of Warrant Shares equivalent to
the number of Warrant Shares remaining unexercised may be issued by the Warrant Agent to the Holder of such Warrant Certificate or to
his duly authorized assigns in accordance with Section 2(d)(ii) of the Warrant, subject to the provisions of Section 6 hereof.

 

Section
9. Cancellation and Destruction of Warrant Certificates. All Warrant Certificates surrendered for the purpose of exercise,
transfer, split up, combination or exchange shall, if surrendered to the Company or to any of its agents, be delivered to the Warrant
Agent for cancellation or in canceled form, or, if surrendered to the Warrant Agent, shall be canceled by it, and no Warrant Certificate
shall be issued in lieu thereof except as expressly permitted by any of the provisions of this Warrant Agreement. The Company shall deliver
to the Warrant Agent for cancellation and retirement, and the Warrant Agent shall so cancel and retire, any other Warrant Certificate
purchased or acquired by the Company otherwise than upon the exercise thereof.

 

Section
10. Certain Representations; Reservation and Availability of Shares of Common Stock or Cash.

 

(a) This
Warrant Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery
hereof by the Warrant Agent, constitutes a valid and legally binding obligation of the Company enforceable against the Company in accordance
with its terms, and the Warrants have been duly authorized, executed and issued by the Company and, assuming due authentication thereof
by the Warrant Agent pursuant hereto and payment therefor by the Holders as provided in the Registration Statement, constitute valid
and legally binding obligations of the Company enforceable against the Company in accordance with their terms and entitled to the benefits
hereof; in each case except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar
laws relating to or affecting creditors’ rights generally or by general equitable principles (regardless of whether such enforceability
is considered in a proceeding in equity or at law).

 

(b) The
Company covenants and agrees that it will cause to be reserved and kept available out of its authorized and unissued shares of Common
Stock or its authorized and issued shares of Common Stock held in its treasury, free from preemptive rights, the number of shares of
Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants.

 

    	13

    	 

    

 

(c) The
Company represents and warrants that: (i) it is duly incorporated and validly existing under the laws of its jurisdiction of incorporation;
(ii) the offer and sale of the Warrants and the execution, delivery and performance of all transactions contemplated thereby (including
this Warrant Agreement) have been duly authorized by all necessary corporate action and will not result in a breach of or constitute
a default under the articles of association, bylaws or any similar document of the Company or any indenture, agreement or instrument
to which it is a party or is bound; (iii) the Warrants will comply in all material respects with all applicable requirements of law;
and (iv) to the best of its knowledge, there is no litigation pending or threatened as of the date hereof in connection with the offering
of the Warrants.

 

(d) The
Company further covenants and agrees that it will pay when due and payable any and all federal and state transfer taxes and charges which
may be payable in respect of the original issuance or delivery of the Warrant Certificates or certificates evidencing Common Stock upon
exercise of the Warrants. The Company shall not, how-ever, be required to pay any tax or governmental charge which may be payable in
respect of any transfer involved in the transfer or delivery of Warrant Certificates or the issuance or delivery of certificates for
Common Stock in a name other than that of the Holder of the Warrant Certificate evidencing Warrants surrendered for exercise or to issue
or deliver any certificate for shares of Common Stock upon the exercise of any Warrants until any such tax or governmental charge shall
have been paid (any such tax or governmental charge being payable by the Holder of such Warrant Certificate at the time of surrender)
or until it has been established to the Company’s reasonable satisfaction that no such tax or governmental charge is due.

 

Section
11. Common Stock Record Date. Each Person in whose name any certificate for shares of Common Stock is issued (or to whose broker’s
account is credited shares of Common Stock through the DWAC system) upon the exercise of Warrants shall for all purposes be deemed to
have become the holder of record for the Common Stock represented thereby on, and such certificate shall be dated, the date on which
submission of the Notice of Exercise was made, provided that the Warrant Certificate evidencing such Warrant is duly surrendered (but
only if required herein) and payment of the Exercise Price (and any applicable transfer taxes) is received on or prior to the Warrant
Share Delivery Date; provided, however, that, if the date of submission of the Notice of Exercise is a date upon which
the Common Stock transfer books of the Company are closed, such Person shall be deemed to have become the record holder of such shares
on, and such certificate shall be dated, the next succeeding day on which the Common Stock transfer books of the Company are open.

 

Section
12. Adjustment of Exercise Price, Number of Shares of Common Stock or Number of the Company Warrants. The Exercise Price, the
number of shares covered by each Warrant and the number of Warrants outstanding are subject to adjustment from time to time as provided
in Section 3 of the Warrant Certificate. In the event that at any time, as a result of an adjustment made pursuant to Section 3 of the
Warrant Certificate, the Holder of any Warrant thereafter exercised shall become entitled to receive any shares of capital stock of the
Company other than shares of Common Stock, thereafter the number of such other shares so receivable upon exercise of any Warrant shall
be subject to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect
to the shares contained in Section 3 of the Warrant Certificate, and the provisions of Sections 8, 12, 13, and 14 of this Warrant Agreement
with respect to the shares of Common Stock shall apply on like terms to any such other shares. All Warrants originally issued by the
Company subsequent to any adjustment made to the Exercise Price pursuant to the Warrant Certificate shall evidence the right to purchase,
at the adjusted Exercise Price, the number of shares of Common Stock purchasable from time to time hereunder upon exercise of the Warrants,
all subject to further adjustment as provided herein.

 

    	14

    	 

    

 

Section
13. Other Adjustments.

 

(a) Adjustment
upon Subdivisions or Combinations. If the Company, at any time while a Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of the
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 13(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification. The Company shall promptly notify the Warrant Agent of
any such adjustment and give specific instructions to the Warrant Agent with respect to any adjustments to the warrant register.

 

(b) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Sections 12 and 13(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of such Holder’s Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record
is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the
extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

(c)
Pro Rata Distributions. During such time as a Holder’s Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of such Holder’s Warrant, then, in each such case, the Holder shall be entitled to participate in
such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common
Stock acquirable upon complete exercise of the Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).

 

    	15

    	 

    

 

(d) Reclassification,
Consolidation, Purchase, Combination, Sale or Conveyance. If, at any time while the Warrants are outstanding, (i) the Company, directly
or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)
the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to
sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons, whereby such other Person or group acquires
more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons
making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or
other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of a Warrant, each
Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to
the occurrence of such Fundamental Transaction at the option of the Holder (without regard to any limitation in Section 8(g) on the exercise
of the Warrants), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which each Warrant is exercisable immediately prior to such Fundamental
Transaction (without regard to any limitation in Section 8(g) on the exercise of the Warrants). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise
Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration that such Holder receives upon any exercise
of each Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in
which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the
Company under this Warrant Agreement in accordance with the provisions of this Section 13(d) pursuant to written agreements in form and
substance reasonably satisfactory to the Holders of a majority in interest of the Warrants then outstanding and approved by such Holder
or Holders (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option and written request of such Holder,
deliver to such Holder in exchange for the applicable Warrants created by this Warrant Agreement a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to the Warrants which are exercisable for a corresponding number
of shares of capital stock of such Successor Entity (or its parent entity), equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of the Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of the Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holders
of a majority in interest of the Warrants then outstanding. Upon the occurrence of any such Fundamental Transaction the Successor Entity
shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant
Agreement and the Warrants referring to the “Company” shall refer instead to the Successor Entity), and may exercise every
right and power of the Company and shall assume all of the obligations of the Company under this Warrant Agreement and the Warrants with
the same effect as if such Successor Entity had been named as the Company herein and therein. The Company shall instruct the Warrant
Agent in writing to mail by first class mail, postage prepaid, to each Holder, written notice of the execution of any such amendment,
supplement or agreement with the Successor Entity. Any supplemented or amended agreement entered into by the successor corporation or
transferee shall provide for adjustments, which shall be as nearly equivalent as may be practicable to the adjustments provided for in
this Section 13(d). The Warrant Agent shall have no duty, responsibility or obligation to determine the correctness of any provisions
contained in such agreement or such notice, including but not limited to any provisions relating either to the kind or amount of securities
or other property receivable upon exercise of Warrants or with respect to the method employed and provided therein for any adjustments,
and shall be entitled to rely conclusively for all purposes upon the provisions contained in any such agreement. The provisions of this
Section 13(d) shall similarly apply to successive reclassifications, changes, consolidations, mergers, sales and conveyances of the kind
described above.

 

    	16

    	 

    

 

(e) Calculations.
All calculations under this Section 13 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 13, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

Section
14. Certification of Adjusted Exercise Price or Number of Shares of Common Stock. Whenever the Exercise Price or the number
of shares of Common Stock issuable upon the exercise of each Warrant is adjusted as provided in Section 12 or 13, the Company shall (i)
promptly prepare a certificate setting forth the Exercise Price of each Warrant as so adjusted, and a brief statement of the facts accounting
for such adjustment, (ii) promptly file with the Warrant Agent and with each transfer agent for the Common Stock a copy of such certificate,
and (iii) instruct the Warrant Agent to send a brief summary thereof to each Holder of a Warrant.

 

Section
15. Notices of Changes in Warrant. Upon every adjustment of the Exercise Price or the number of Warrant Shares issuable upon
exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price
resulting from such adjustment and the increase or decrease, if any, in the number of Warrant Shares purchasable at such price upon the
exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.
Upon the occurrence of any event specified in Sections 12, 13(a), 13(b), 13(c), or 13(d), then, in any such event, the Company shall
give written notice to each Holder, at the last address set forth for such holder in the Warrant Register, as of the record date or the
effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.
The Warrant Agent shall be entitled to rely conclusively on, and shall be fully protected in relying on, any certificate, notice or instructions
provided by the Company with respect to any adjustment of the Exercise Price or the number of shares issuable upon exercise of a Warrant,
or any related matter, and the Warrant Agent shall not be liable for any action taken, suffered or omitted to be taken by it in accordance
with any such certificate, notice or instructions or pursuant to this Warrant Agreement. The Warrant Agent shall not be deemed to have
knowledge of any such adjustment unless and until it shall have received written notice thereof from the Company.

 

Section
16. No Fractional Exercise.

 

(a) The
Company shall not issue fractions of Warrants or distribute a Global Warrant or Warrant Certificates that evidence fractional Warrants.
Whenever any fractional Warrant would otherwise be required to be issued or distributed, the actual issuance or distribution shall reflect
a rounding of such fraction either up or down to the nearest whole Warrant.

 

(b) No
fractional Warrant Shares will be issued upon the exercise of the Warrant. If, by reason of any adjustment made pursuant to Sections
12 or 13, a Holder would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall,
upon such exercise, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by
the Exercise Price or round up to the next whole share.

 

    	17

    	 

    

 

Section
17. Restrictive Legends. In the event that a Warrant Certificate surrendered for transfer bears a restrictive legend, the Warrant
Agent shall not register that transfer until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer
may be made and indicating whether the Warrants must also bear a restrictive legend upon that transfer.

 

Section
18. Other Provisions Relating to Rights of Holders of Warrants.

 

(a) No
Rights as Stockholder. Except as otherwise specifically provided herein, a Holder, solely in its capacity as a holder of Warrants,
shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall
anything contained in this Warrant Agreement be construed to confer upon a Holder, solely in its capacity as the registered holder of
Warrants, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether
any reorganization, issue of stock, reclassification of share capital, consolidation, merger, conveyance or otherwise), receive notice
of meetings, receive dividends or subscription rights or rights to participate in new issues of shares, or otherwise, prior to the issuance
to the Holder of the Warrant Shares which it is then entitled to receive upon the due exercise of Warrants.

 

(b) Reservation
of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Common
Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Warrant Agreement.

 

Section
19. Conditions of Warrant Agent’s Obligations. The Warrant Agent accepts its obligations herein set forth upon the terms
and conditions hereof, including the following to all of which the Company agrees and to all of which the rights hereunder of the Holders
from time to time of the Warrant shall be subject:

 

(a) Instructions.
Any instructions given to the Warrant Agent orally, as permitted by any provision of this Warrant Agreement, shall be confirmed in writing
by the Company as soon as practicable. The Warrant Agent shall not be liable or responsible and shall be fully authorized and protected
for acting, or failing to act, in accordance with any oral instructions which do not conform with the written confirmation received in
accordance with this Section 19.

 

(b) Compensation.

 

(i) Whether
or not any Warrants are exercised, for the Warrant Agent’s services as agent for the Company hereunder, the Company shall pay to
the Warrant Agent such fees as may be separately agreed between the Company and Warrant Agent and the Warrant Agent’s out of pocket
expenses in connection with this Warrant Agreement, including, without limitation, the fees and expenses of the Warrant Agent’s
counsel. While the Warrant Agent endeavors to maintain out-of-pocket charges (both internal and external) at competitive rates, these
charges may not reflect actual out-of-pocket costs, and may include handling charges to cover internal processing and use of the Warrant
Agent’s billing systems.

 

    	18

    	 

    

 

(ii) All
amounts owed by the Company to the Warrant Agent under this Warrant Agreement are due within 30 days of the invoice date. Delinquent
payments are subject to a late payment charge of one and one-half percent (1.5%) per month commencing 45 days from the invoice date.
The Company agrees to reimburse the Warrant Agent for any attorney’s fees and any other costs associated with collecting delinquent
payments.

 

(iii) No
provision of this Warrant Agreement shall require Warrant Agent to expend or risk its own funds or otherwise incur any financial liability
in the performance of any of its duties under this Warrant Agreement or in the exercise of its rights.

 

(c) Rights
and Duties of Warrant Agent. As agent for the Company hereunder the Warrant Agent:

 

(i) shall
have no duties or obligations other than those specifically set forth herein or as may subsequently be agreed to in writing by the Warrant
Agent and the Company;

 

(ii) shall
be regarded as making no representations and having no responsibilities as to the validity, sufficiency, value, or genuineness of the
Warrants or any Warrant Shares;

 

(iii) shall
not be obligated to take any legal action hereunder; if, however, the Warrant Agent determines to take any legal action hereunder, and
where the taking of such action might, in its judgment, subject or expose it to any expense or liability it shall not be required to
act unless it has been furnished with an indemnity reasonably satisfactory to it;

 

(iv) may
rely on and shall be fully authorized and protected in acting or failing to act upon any certificate, instrument, opinion, notice, letter,
telegram, telex, facsimile transmission or other document or security delivered to the Warrant Agent and believed by it to be genuine
and to have been signed by the proper party or parties;

 

(v) shall
not be liable or responsible for any recital or statement contained in the Registration Statement or any other documents relating thereto;

 

(vi) shall
not be liable or responsible for any failure on the part of the Company to comply with any of its covenants and obligations relating
to the Warrants, including without limitation obligations under applicable securities laws;

 

(vii) may
rely on and shall be fully authorized and protected in acting or failing to act upon the written, telephonic or oral instructions with
respect to any matter relating to its duties as Warrant Agent covered by this Warrant Agreement (or supplementing or qualifying any such
actions) of officers of the Company, and is hereby authorized and directed to accept instructions with respect to the performance of
its duties hereunder from the Company or counsel to the Company, and may apply to the Company, for advice or instructions in connection
with the Warrant Agent’s duties hereunder, and the Warrant Agent shall not be liable for any delay in acting while waiting for
those instructions; any applications by the Warrant Agent for written instructions from the Company may, at the option of the Agent,
set forth in writing any action proposed to be taken or omitted by the Warrant Agent under this Warrant Agreement and the date on or
after which such action shall be taken or such omission shall be effective; the Warrant Agent shall not be liable for any action taken
by, or omission of, the Warrant Agent in accordance with a proposal included in such application on or after the date specified in such
application (which date shall not be less than five Business Days after the date such application is sent to the Company, unless the
Company shall have consented in writing to any earlier date) unless prior to taking any such action, the Warrant Agent shall have received
written instructions in response to such application specifying the action to be taken or omitted;

 

    	19

    	 

    

 

(viii) may
consult with counsel satisfactory to the Warrant Agent, including its in-house counsel, and the advice of such counsel shall be full
and complete authorization and protection in respect of any action taken, suffered, or omitted by it hereunder in good faith and in accordance
with the advice of such counsel;

 

(ix) may
perform any of its duties hereunder either directly or by or through nominees, correspondents, designees, or subagents, and it shall
not be liable or responsible for any misconduct or negligence on the part of any nominee, correspondent, designee, or subagent appointed
with reasonable care by it in connection with this Warrant Agreement;

 

(x) is
not authorized, and shall have no obligation, to pay any brokers, dealers, or soliciting fees to any Person; and

 

(xi) shall
not be required hereunder to comply with the laws or regulations of any country other than the United States of America or any political
subdivision thereof.

 

(d) Indemnification.

 

(i) In
the absence of gross negligence or willful or illegal misconduct on its part, the Warrant Agent shall not be liable for any action taken,
suffered, or omitted by it or for any error of judgment made by it in the performance of its duties under this Warrant Agreement. Anything
in this Warrant Agreement to the contrary notwithstanding, in no event shall Warrant Agent be liable for special, indirect, incidental,
consequential or punitive losses or damages of any kind whatsoever (including but not limited to lost profits), even if the Warrant Agent
has been advised of the possibility of such losses or damages and regardless of the form of action. Any liability of the Warrant Agent
will be limited in the aggregate to the amount of fees paid by the Company hereunder. The Warrant Agent shall not be liable for any failures,
delays or losses, arising directly or indirectly out of conditions beyond its reasonable control including, but not limited to, acts
of government, exchange or market ruling, suspension of trading, work stoppages or labor disputes, fires, civil disobedience, riots,
rebellions, storms, electrical or mechanical failure, computer hardware or software failure, communications facilities failures including
telephone failure, war, terrorism, insurrection, earthquakes, floods, acts of God or similar occurrences.

 

(ii) In
the event any question or dispute arises with respect to the proper interpretation of the Warrants or the Warrant Agent’s duties
under this Warrant Agreement or the rights of the Company or of any Holder, the Warrant Agent shall not be required to act and shall
not be held liable or responsible for its refusal to act until the question or dispute has been judicially settled (and, if appropriate,
it may file a suit in interpleader or for a declaratory judgment for such purpose) by final judgment rendered by a court of competent
jurisdiction, binding on all Persons interested in the matter which is no longer subject to review or appeal, or settled by a written
document in form and substance satisfactory to Warrant Agent and executed by the Company and each such Holder. In addition, the Warrant
Agent may require for such purpose, but shall not be obligated to require, the execution of such written settlement by all the Holders
and all other Persons that may have an interest in the settlement.

 

    	20

    	 

    

 

(iii) The
Company covenants to indemnify the Warrant Agent and hold it harmless from and against any loss, liability, claim or expense (“Loss”)
arising out of or in connection with the Warrant Agent’s duties under this Warrant Agreement, including the costs and expenses
of defending itself against any Loss, unless such Loss shall have been determined by a court of competent jurisdiction to be a result
of the Warrant Agent’s gross negligence or willful misconduct.

 

(e) Expiration
of Agreement; Survivability. Unless terminated earlier by the parties hereto, this Warrant Agreement shall terminate 90 days after
the earlier of the Termination Date and the date on which no Warrants remain outstanding (the “Expiration Date”).
On the Business Day following the Expiration Date, the Agent shall deliver to the Company any entitlements, if any, held by the Warrant
Agent under this Warrant Agreement. The Agent’s right to be reimbursed for fees, charges and out-of-pocket expenses as provided
in this Section 19 shall survive the termination of this Warrant Agreement.

 

Section
20. Concerning the Warrant Agent and Other Matters.

 

(a) Severability.
If any provision of this Warrant Agreement shall be held illegal, invalid, or unenforceable by any court, this Warrant Agreement shall
be construed and enforced as if such provision had not been contained herein and shall be deemed an Agreement among the parties to it
to the full extent permitted by applicable law.

 

(b) Inconsistency.
In the event of inconsistency between this Warrant Agreement and the descriptions in the Registration Statement, as they may from time
to time be amended, the terms of this Warrant Agreement shall control.

 

(c) Authorized
Representatives. Set forth in Exhibit 5 hereto is a list of the names and specimen signatures of the Persons authorized to
act for the Company under this Warrant Agreement (the “Authorized Representatives”). The Company shall, from time
to time, certify to you the names and signatures of any other Persons authorized to act for the Company under this Warrant Agreement.

 

(d) Notice.
Except as expressly set forth elsewhere in this Warrant Agreement, all notices, instructions and communications under this Warrant Agreement
shall be in writing, shall be effective upon receipt and shall be addressed: (i) if to the Company, to bioAffinity Technologies Inc.,
22211 W Interstate 10, Suite 1206, San Antonio, Texas 78257, Attention: Maria Zannes, President & CEO, with a copy (which shall not
constitute notice) to Dykema Gossett PLLC, 112 E. Pecan Street, Suite 1800, Attention: Wilhelm Liebmann, Esq.; or (ii) if to the Warrant
Agent, to VStock Transfer, LLC 18 Lafayette Place, Woodmere, New York 11598, or to such other address of which a party hereto has notified
the other party.

 

    	21

    	 

    

 

(e) Governing
Law. This Warrant Agreement shall be governed by and construed in accordance with the laws of the State of New York. All actions
and proceedings relating to or arising from, directly or indirectly, this Warrant Agreement may be litigated in courts located within
the Borough of Manhattan in the City and State of New York. The Company hereby submits to the personal jurisdiction of such courts and
consents that any service of process may be made by certified or registered mail, return receipt requested, directed to the Company at
its address last specified for notices hereunder. Each of the parties hereto hereby waives the right to a trial by jury in any action
or proceeding arising out of or relating to this Warrant Agreement.

 

(f) Assignment.
This Warrant Agreement shall inure to the benefit of and be binding upon the successors and assigns of the parties hereto. This Warrant
Agreement may not be assigned, or otherwise transferred, in whole or in part, by either party without the prior written consent of the
other party, which the other party will not unreasonably withhold, condition or delay; except that (1) consent is not required for an
assignment or delegation of duties by Warrant Agent to any affiliate of Warrant Agent and (2) any reorganization, merger, consolidation,
sale of assets or other form of business combination by Warrant Agent or the Company shall not be deemed to constitute an assignment
of this Warrant Agreement.

 

(g) Amendments.
No provision of this Warrant Agreement may be amended, modified or waived, except in a written document signed by both parties. The Company
and the Warrant Agent may amend or supplement this Warrant Agreement without the consent of any Holder for the purpose of curing any
ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions
with respect to matters or questions arising under this Warrant Agreement as the parties may deem necessary or desirable and that the
parties determine, in good faith, shall not adversely affect the interest of the Holders. All other amendments and supplements shall
require the vote or written consent of Holders of at least 50.1% of the then outstanding Warrants, provided that adjustments may be made
to the Warrant terms and rights in accordance with Sections 12 and 13 without the consent of the Holders unless otherwise stated herein.

 

(h) Payment
of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant
Agent in respect of the issuance or delivery of Warrant Shares upon the exercise of Warrants, but the Company may require the Holders
to pay any transfer taxes in respect of the Warrants or such shares. The Warrant Agent may refrain from registering any transfer of Warrants
or any delivery of any Warrant Shares unless or until the Persons requesting the registration or issuance shall have paid to the Warrant
Agent for the account of the Company the amount of such tax or charge, if any, or shall have established to the reasonable satisfaction
of the Company and the Warrant Agent that such tax or charge, if any, has been paid.

 

    	22

    	 

    

 

(j) Resignation
of Warrant Agent.

 

(i) Appointment
of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged
from all further duties and liabilities hereunder after giving thirty (30) days’ notice in writing to the Company, or such shorter
period of time agreed to by the Company. The Company may terminate the services of the Warrant Agent, or any successor Warrant Agent,
after giving thirty (30) days’ notice in writing to the Warrant Agent or successor Warrant Agent, or such shorter period of time
as agreed. If the office of the Warrant Agent becomes vacant by resignation, termination or incapacity to act or otherwise, the Company
shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment
within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent, then the Warrant
Agent or any Holder may apply to any court of competent jurisdiction for the appointment of a successor Warrant Agent at the Company’s
cost. Pending appointment of a successor to such Warrant Agent, either by the Company or by such a court, the duties of the Warrant Agent
shall be carried out by the Company. Any successor Warrant Agent (but not including the initial Warrant Agent), whether appointed by
the Company or by such court, shall be a Person organized and existing under the laws of any state of the United States of America, in
good standing, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal
or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities,
duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without
any further act or deed, and except for executing and delivering documents as provided in the sentence that follows, the predecessor
Warrant Agent shall have no further duties, obligations, responsibilities or liabilities hereunder, but shall be entitled to all rights
that survive the termination of this Warrant Agreement and the resignation or removal of the Warrant Agent, including but not limited
to its right to indemnity hereunder. If for any reason it becomes necessary or appropriate or at the request of the Company, the predecessor
Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all
the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company
shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming
to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

 

(ii) Notice
of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the
predecessor Warrant Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.

 

(iii) Merger
or Consolidation of Warrant Agent. Any Person into which the Warrant Agent may be merged or converted or with which it may be consolidated
or any Person resulting from any merger, conversion or consolidation to which the Warrant Agent shall be a party or any Person succeeding
to the shareowner services business of the Warrant Agent or any successor Warrant Agent shall be the successor Warrant Agent under this
Warrant Agreement, without any further act or deed.

 

Section
20. Miscellaneous Provisions.

 

(j) Persons
Having Rights under this Warrant Agreement. Nothing in this Warrant Agreement expressed and nothing that may be implied from any
of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any Person or corporation other than the parties
hereto and the Holders any right, remedy, or claim under or by reason of this Warrant Agreement or of any covenant, condition, stipulation,
promise, or agreement hereof.

 

(k) Examination
of the Warrant Agreement. A copy of this Warrant Agreement shall be available at all reasonable times at the office of the Warrant
Agent designated for such purpose for inspection by any Holder. Prior to such inspection, the Warrant Agent may require any such holder
to provide reasonable evidence of its interest in the Warrants.

 

(l) Counterparts.
This Warrant Agreement may be executed in any number of original, facsimile or electronic counterparts and each of such counterparts
shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

(m) Effect
of Headings. The Section headings herein are for convenience only and are not part of this Warrant Agreement and shall not affect
the interpretation thereof.

 

[Signature
Page to Follow]

 

    	23

    	 

    

 

IN
WITNESS WHEREOF, this Warrant Agent Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

	 	BIOAFFINITY
    TECHNOLOGIES, INC.
	 	 	 
	 	By:	/s/
    Maria Zannes
	 	Name:	Maria
    Zannes
	 	Title:	President
    & CEO
	 	 	 
	 	VSTOCK
    TRANSFER, LLC
	 	 	 
	 	By:	/s/
    Young D. Kim
	 	Name:	Young
    D. Kim
	 	Title:	Compliance
    Officer

 

    	 

     

    

 

ANNEX
A: Form of Warrant Certificate Request Notice

 

WARRANT
CERTIFICATE REQUEST NOTICE

 

To:
VStock Transfer, LLC as Warrant Agent for bioAffinity Technologies, Inc. (the “Company”)

 

The
undersigned Holder of Common Stock Purchase Warrants (“Warrants”) in the form of Global Warrants issued by the Company
hereby elects to receive a Warrant Certificate evidencing the Warrants held by the Holder as specified below:

 

	1.	Name
    of Holder of Warrants in form of Global Warrants: _____________________________
	 	 
	2.	Name
    of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants): ________________________________
	 	 
	3.	Number
    of Warrants in name of Holder in form of Global Warrants: ___________________
	 	 
	4.	Number
    of Warrants for which Warrant Certificate shall be issued: __________________
	 	 
	5.	Number
    of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any: ___________
	 	 
	6.	Warrant
    Certificate shall be delivered to the following address:
	 	 
	 	______________________________
	 	 
	 	______________________________
	 	 
	 	______________________________
	 	 
	 	______________________________

 

The
undersigned hereby acknowledges and agrees that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate,
the Holder is deemed to have surrendered the number of Warrants in form of Global Warrants in the name of the Holder equal to the number
of Warrants evidenced by the Warrant Certificate.

 

	[SIGNATURE
    OF HOLDER]	 
	 	 
	Name
    of Investing Entity: _______________________________________________________	 
	 	 
	Signature
    of Authorized Signatory of Investing Entity: _________________________________	 
	 	 
	Name
    of Authorized Signatory: ___________________________________________________	 
	 	 
	Title
    of Authorized Signatory: ____________________________________________________	 
	 	 
	Date:
    _______________________________________________________________________	 

 

    	 

     

    

 

EXHIBIT
1

 

[TO
BE INCLUDED IN THE TRADEABLE Warrant CERTIFICATE]

 

Unless
this certificate is presented by an authorized representative of The Depository Trust Company, a New York corporation (“the Depositary”),
to issuer or its agent for registration of transfer, exchange, or payment, and any certificate issued is registered in the name of Cede
& Co. or in such other name as is requested by an authorized representative of the Depositary (and any payment is made to Cede &
Co. or to such other entity as is requested by an authorized representative of the Depositary), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF
FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, Cede & Co., has an interest herein.

 

BIOAFFINITY
TECHNOLOGIES, INC.

WARRANT
CERTIFICATE

NOT
EXERCISABLE AFTER September [*], 2027

 

This
certifies that the Person whose name and address appears below, or registered assigns, is the registered owner of the number of Warrants
set forth below. Each Warrant entitles its registered holder to purchase from bioAffinity Technologies, Inc., a company incorporated
under the laws of the State of Delaware (the “Company”), at any time prior to 11:59 P.M. (New York City time) on September
[*], 2027, one share of common stock, par value $0.007 per share, of the Company (each, a “Warrant Share” and collectively,
the “Warrant Shares”), at an exercise price of $7.35 per share, subject to possible adjustments as provided in the
Warrant Agreement (as defined below).

 

This
Warrant Certificate, with or without other Warrant Certificates, upon surrender at the designated office of the Warrant Agent, may be
exchanged for another Warrant Certificate or Warrant Certificates evidencing the same number of Warrants as the Warrant Certificate or
Warrant Certificates surrendered. A transfer of the Warrants evidenced hereby may be registered upon surrender of this Warrant Certificate
at the designated office of the Warrant Agent by the registered holder in person or by a duly authorized attorney, properly endorsed
or accompanied by proper instruments of transfer, a signature guarantee, and such other and further documentation as the Warrant Agent
may reasonably request and duly stamped as may be required by the laws of the State of New York and of the United States of America.

 

The
terms and conditions of the Warrants and the rights and obligations of the holder of this Warrant Certificate are set forth in the Warrant
Agent Agreement dated as of September [*], 2022 (the “Warrant Agreement”) between the Company and VStock Transfer,
LLC (the “Warrant Agent”). A copy of the Warrant Agreement is available for inspection during business hours at the
office of the Warrant Agent.

 

    	 

     

    

 

This
Warrant Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by an authorized signatory
of the Warrant Agent.

 

WITNESS
the facsimile signature of a proper officer of the Company.

 

	 	BIOAFFINITY
    TECHNOLOGIES, INC.
	 	 	 
	 	By:	
	 	Name:	Maria
    Zannes
	 	Title:	President
    & CEO

 

	Dated:	______________              	 
	 	 	 
	Countersigned:	 

 

	VSTOCK
    TRANSFER, LLC	 
	 	 	 
	By:		 
	Name:		 
	Title:	          	 

 

PLEASE
DETACH HERE

 

 

 

Certificate
No.:_________ Number of Warrants:__________

 

WARRANT
CUSIP NO.: 09076W 117

 

BIOAFFINITY
TECHNOLOGIES, INC.

 

    	 

     

    

 

EXHIBIT
2

 

[TO
BE INCLUDED IN THE NON-TRADEABLE WARRANT CERTIFICATE]

 

BIOAFFINITY
TECHNOLOGIES, INC.

WARRANT
CERTIFICATE

NOT EXERCISABLE AFTER September [*], 2027

 

This
certifies that the Person whose name and address appears below, or registered assigns, is the registered owner of the number of Warrants
set forth below. Each Warrant entitles its registered holder to purchase from bioAffinity Technologies, Inc., a company incorporated
under the laws of the State of Delaware (the “Company”), at any time prior to 11:59 P.M. (New York City time) on September
[*], 2027, one share of common stock, par value $0.007 per share, of the Company (each, a “Warrant Share” and collectively,
the “Warrant Shares”), at an exercise price of $7.656 per share, subject to possible adjustments as provided in the
Warrant Agreement (as defined below).

 

This
Warrant Certificate, with or without other Warrant Certificates, upon surrender at the designated office of the Warrant Agent, may be
exchanged for another Warrant Certificate or Warrant Certificates evidencing the same number of Warrants as the Warrant Certificate or
Warrant Certificates surrendered. A transfer of the Warrants evidenced hereby may be registered upon surrender of this Warrant Certificate
at the designated office of the Warrant Agent by the registered holder in person or by a duly authorized attorney, properly endorsed
or accompanied by proper instruments of transfer, a signature guarantee, and such other and further documentation as the Warrant Agent
may reasonably request and duly stamped as may be required by the laws of the State of New York and of the United States of America.

 

The
terms and conditions of the Warrants and the rights and obligations of the holder of this Warrant Certificate are set forth in the Warrant
Agent Agreement dated as of September [*], 2022 (the “Warrant Agreement”) between the Company and VStock Transfer,
LLC (the “Warrant Agent”). A copy of the Warrant Agreement is available for inspection during business hours at the
office of the Warrant Agent.

 

This
Warrant Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by an authorized signatory
of the Warrant Agent.

 

WITNESS
the facsimile signature of a proper officer of the Company.

 

	 	BIOAFFINITY
    TECHNOLOGIES, INC.
	 	 	 
	 	By:	 
	 	Name:	Maria
    Zannes
	 	Title:	President
    & CEO

 

	Dated:	______________             	 
	 	 	 
	Countersigned:	 

 

	VSTOCK
    TRANSFER, LLC	 
	 	 	 
	By:		 
	Name:	          	 
	Title:		 

 

PLEASE
DETACH HERE

 

 

 

Certificate
No.:_________ Number of Warrants:__________

 

BIOAFFINITY
TECHNOLOGIES, INC.

 

    	 

     

    

 

EXHIBIT
3

 

[Form
of Notice of Exercise]

 

(To
Be Executed Upon Exercise Of Warrants not evidenced by a Warrant Certificate)

 

TO:
BIOAFFINITY TECHNOLOGIES, INC.

 

(1)
The undersigned hereby elects to purchase [●] Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

[  ] in lawful money of the United States; or

 

[  ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 	 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

(4)
Accredited Investor. If the Warrant is being exercised via cash exercise, the undersigned is an “accredited investor”
as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ___________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _____________________________________________________

Name
of Authorized Signatory: _______________________________________________________________________ 

Title
of Authorized Signatory: ________________________________________________________________________ 

Date:
___________________________________________________________________________________________ 

 

    	 

     

    

 

EXHIBIT
4

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	____________________________________________
	 	(Please
    Print)
	 	 
	Address:	____________________________________________
	 	(Please
    Print)
	 	 
	Phone
    Number:	____________________________________________
	 	 
	Email
    Address:	_____________________________________________
	 	 
	Dated:
    _______________ __, ______	 
	 	 
	Holder’s
    Signature: __________________________	 
	 	 
	Holder’s
    Address: ___________________________	 

 

    	 

     

    

 

EXHIBIT
5

 

AUTHORIZED
REPRESENTATIVES

 

	Name	 	Title	 	Signature
	Maria
    Zannes	 	President/

    Chief
    Executive Officerformofseparationagreemen

, 2022  VIA PERSONAL DELIVERY  James Mullen  Dear James:  This letter (the “Agreement”) confirms the agreement between you and TuSimple  Holdings, Inc. (the “Company”) regarding the terms described below.  1. Resignation Date.   Your employment with the Company will end on  September 30, 2022 (the “Resignation Date”).  During the remainder of your employment with the  Company, you will continue to be paid your current base salary and the Company will provide you  all employee benefits to which you are entitled.  You understand and agree that during the  remainder of your employment with the Company you will perform your job to the best of your  ability and in good faith and that you will comply with all Company policies.  2. Final Pay and COBRA Insurance Benefits.  Regardless of whether you  sign this Agreement, on the Resignation Date, the Company will provide your final pay, which  represents all of your (i) earned but unpaid compensation, less lawful deductions and (ii) accrued  but unused vacation time or PTO (the “Final Pay”).  Under separate cover following the  Resignation Date, you will receive information about your rights, if any, to continue your  participation in the Company’s health insurance plan under the Consolidated Omnibus Budget  Reconciliation Act (“COBRA”). You acknowledge that, the only payments and benefits that you  are entitled to receive from the Company in the future are those specified in this Agreement.   Except as set forth herein, you will not be eligible to participate or continue to participate in any  employee benefit plans or compensation arrangements of the Company subsequent to the  Resignation Date.  3. Effective Date and Revocation.  You have up to 21 days after you receive  this Agreement to review it.  However, you may sign and return this Agreement sooner if you  wish; provided, however, that you may not sign this Agreement prior to the Resignation Date.   You agree that changes to this Agreement, whether material or immaterial, do not restart the  running of the 21-calendar day period.  You are advised to consult an attorney of your own  choosing before signing this Agreement.  You represent that you have had the opportunity to  review this Agreement and, specifically, the release in Section 7 of this Agreement, with an  attorney of your choice. You also agree and acknowledge that you are receiving benefits and  payments to which you would not otherwise be entitled unless you sign this Agreement, that you  have voluntarily consented to the release set forth in Section 7 of this Agreement and that you have  entered into this Agreement freely, knowingly and voluntarily.  Furthermore, you have up to seven days after you sign this Agreement to revoke your consent to  this Agreement.  If you wish to revoke your consent to this Agreement after signing it, you may  do so by delivering a letter of revocation to me.  If you do not revoke this Agreement, the eighth  day after the date you sign it will be the “Effective Date.”  Because of the seven-day revocation  period, no part of this Agreement will become effective or enforceable until the Effective Date.   

 

  4. Waiver of Company Rights to Repayment of Retention  Bonus.  Pursuant to the terms of the retention bonus letter between you and the Company dated  April 11, 2022 (the “Retention Bonus Letter”), you acknowledge that you were paid an advance  of a retention bonus in the amount of $500,000 (the “Retention Bonus”), subject to your continued  employment with the Company or a wholly-owned subsidiary through April 11, 2023. Because  the Resignation Date will occur before April 11, 2023, you acknowledge that under the terms of  the Retention Bonus Letter you are responsible for repaying the full amount of the Retention Bonus  to the Company, net of any applicable withholding taxes and other deductions required by law,  within 5 days of the Resignation Date. However, in consideration for you signing and not revoking  this Agreement and your compliance with all of the terms set forth in this Agreement, you shall  not be required to pay back any portion of the Retention Bonus.    5. Equity Awards.  The Company previously granted you options to purchase  shares of the Company’s Common Stock (the “Options”) pursuant to the Company’s 2017 Stock  Plan (as amended) (the “2017 Plan”) and the Company’s 2021 Equity Incentive Plan (the “2021  EIP”) (collectively, the “Plans”) and all applicable award agreements.    Subject to your execution and non-revocation of this Agreement, your continued compliance with  the requirements contained or described herein, the Company has extended the post-termination  exercise period of each of the Options, such that you will be eligible to exercise each of them (until  the earlier of: (i) the two-year anniversary of the Resignation Date, (ii) the date on which any of  the Options are terminated in connection with the occurrence of certain corporate transactions, as  described in Section 10(b) of the 2017 Plan and Section 9.3 of the 2021 EIP, and (iii) the original  term of the Options (the “Extended Option Exercise Period”).     You acknowledge and agree that the Options shall continue to be subject to the terms and  conditions of the Plans and applicable award agreements and that you do not have any other rights  to receive, acquire, possess or vest into any additional shares of the Company’s Common Stock or  any other shares, warrants, securities, derivative securities or other class of capital stock of the  Company or any of its parent, subsidiary or affiliated entities.  6. Certain Payments and Benefits.  Subject to your execution and non- revocation of this Agreement and your continued compliance with the requirements contained or  described herein, the Company will provide you with the following payments and benefits: (i)  continued payment of your base salary as in effect as of the date hereof for a period of twelve (12)  months following the Resignation Date, which shall be paid in the form of salary continuation in  accordance with the Company’s standard payroll procedures; (ii) to the extent that you timely elect  continued coverage under COBRA, the Company shall pay the same portion of the monthly  premium under COBRA as it pays for active employees and their eligible dependents until the  earliest of (x) the last day of the period ending on the date that is twelve (12) months following the  Resignation Date, (y) the expiration of your continuation coverage under COBRA or (z) the date  that you becomes eligible for substantially equivalent health insurance coverage in connection with  new employment; and (iii) the total number of vested shares subject to each of your equity awards  outstanding as of the Resignation Date subject to time-based vesting shall be determined by adding  twelve (12) months to your actual period of employment as of the Resignation Date and, in the  case of equity awards with performance-based vesting, all performance goals and other vesting  criteria will be deemed satisfied in accordance with the terms set forth in the award agreement  

 

  evidencing the applicable equity award.  All such payments and benefits will be provided, paid or  commence as of or as soon as administratively practicable following the Effective Date (and,  where applicable, will include at such time any amounts accrued from the Resignation Date) and,  if the period in Section 4 spans two calendar years, then such benefit will in any event be provided,  paid or commence in the second calendar year.  You hereby acknowledge and agree that, except  as expressly provided under this Agreement, the foregoing payments and benefits are in full  satisfaction of any contractual severance entitlements that you may have with the Company as of  the Resignation Date.  7. Release of All Claims.  To the fullest extent permitted by law, you, for and  on behalf of yourself and your heirs, executors, administrators, successors and assigns, hereby  voluntarily, knowingly and willingly waive, release and forever discharge any and all claims or  causes of action, whether or not now known, against the Company or its predecessors, successors  or past or present subsidiaries, affiliates, stockholders, owners, directors, officers, employees,  consultants, attorneys, agents, representatives, assigns and employee benefit plans, and each of  their subsidiaries, affiliates, estates, predecessors, successors and assigns (each, individually, a  “Company Releasee,” collectively referred to as the “Company Releasees”) with respect to any  matter, including (without limitation) any matter related to your employment with the Company  or the termination of that employment, including (without limitation) claims to attorneys’ fees or  costs, claims of wrongful discharge, constructive discharge, emotional distress, defamation,  invasion of privacy, fraud, breach of contract or breach of the covenant of good faith and fair  dealing and any claims of discrimination or harassment based on sex, age, race, national origin,  disability or any other basis under Title VII of the Civil Rights Act of 1964, the Equal Pay Act,  the Age Discrimination in Employment Act of 1967, the Older Workers Benefit Protection Act,  the Americans with Disabilities Act, the National Labor Relations Act, the Family and Medical  Leave Act, the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), the  Worker Adjustment and Retraining Notification (“WARN”) Act, and all other federal, state and  local laws and regulations relating to employment that may be legally waived and released.   However, this release covers only those claims that arose prior to the execution of this Agreement  and only those claims that may be waived by applicable law.  Execution of this Agreement does  not bar (i) a claim for breach of this Agreement, (ii) any claim for coverage under any D&O or  other similar insurance policy or (iii) any claim for indemnification under any written agreement  with the Company, Company bylaws or applicable law.  You understand that this Agreement does not limit your ability to file a charge or complaint with  the Equal Employment Opportunity Commission, the Securities and Exchange Commission or any  other federal, state or local governmental agency or commission (each, a “Government Agency”).   You further understand that nothing in this Agreement or any other agreement that you have with  the Company shall limit your ability to communicate with, or otherwise participate in, to the extent  permitted by applicable law and in accordance with the Rules of Professional Responsibility in the  states in which you are licensed to practice law and/or provide services as counsel, any  investigation or proceeding that may be conducted by, a Government Agency.    You hereby further acknowledge and agree that the Company and all other Company Releasees  have fully satisfied any and all obligations whatsoever owed to you arising out of your employment  with the Company or any other Company Releasee, and that no further payments or benefits are  owed to you by the Company or any other Company Releasee.  

 

  8. Legal Fees.  In the event you file an action based on any claim released  pursuant to Section 7 of this Agreement, the Company shall be entitled to any and all legal fees  and expenses arising out of or relating to such claim.  9. No Admission.  Nothing contained in this Agreement will constitute or be  treated as an admission by you or the Company of liability, any wrongdoing or any violation of  law.  Neither this Agreement nor any of its terms may be used as an admission or introduced as  evidence as to any issue of law or fact in any proceeding, suit or action, other than an action to  enforce this Agreement.  10. Other Agreements.  At all times in the future, you will remain bound by  your Proprietary Information and Inventions Agreement with the Company. This Agreement  renders null and void all prior agreements between you and the Company and constitutes the entire  agreement between you and the Company regarding the subject matter of this Agreement.  This  Agreement may be modified only in a written document signed by you and a duly authorized  officer of the Company.  11. Company Property.  You represent that you have returned to the Company  all property that belongs to the Company, including (without limitation) copies of documents that  belong to the Company and files stored on your computer(s) that contain information belonging to  the Company; provided, however, that you may retain documents and information regarding your  compensation and benefits as an employee of the Company.  12. No Disparagement.  You agree that you will never make any negative or  disparaging statements (orally or in writing) about the Company or its stockholders, directors,  officers, employees, products, services or business practices, except as required by law. The  Company agrees that it will never make any negative or disparaging statements (orally or in  writing) about you except as required by law.    13. Severability.  If any term of this Agreement is held to be invalid, void or  unenforceable, the remainder of this Agreement will remain in full force and effect and will in no  way be affected, and the parties will use their best efforts to find an alternate way to achieve the  same result.  14. Choice of Law and Venue.  This Agreement will be construed and  interpreted in accordance with the laws of the State of Delaware (other than their choice-of-law  provisions). Any dispute regarding the meaning, effect or validity of this Agreement or any  provision thereof shall be resolved in accordance with the laws of the State of Delaware, without  regard to the conflict of laws provisions thereof.  Any legal action or proceeding relating to this  Agreement shall be brought exclusively in the state or federal courts located in or with jurisdiction  over New Castle County, Delaware, and each party consents to the jurisdiction thereof.  You  hereby acknowledge and agree that you are individually represented by your own legal counsel in  negotiating the terms of this Agreement, including without limitation all of the terms of this  paragraph.  15. Execution.  This Agreement may be executed in counterparts, each of  which will be considered an original, but all of which together will constitute one agreement.   

 

  Execution of a facsimile copy will have the same force and effect as execution of an original, and  a facsimile or .pdf signature will be deemed an original and valid signature.  [SIGNATURE PAGE FOLLOWS]     

 

    Please indicate your agreement with the above terms by signing below.    TUSIMPLE HOLDINGS, INC.  By:     Xiaodi Hou  Chief Executive Officer  I agree to the terms of this Agreement, and I am voluntarily signing this release of all claims.  I  acknowledge that I have read and understand this Agreement, and I understand that I cannot pursue  any of the claims and rights that I have waived in this Agreement at any time in the future.       Signature of James Mullen  Dated:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]